<rdf:RDF xmlns:bam="http://www.elsevier.com/xml/schema/rdf/BasicAssetMetadata-1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:pav="http://purl.org/swan/pav/provenance/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:rgn="http://www.elsevier.com/xml/schema/rdf/LDR-Satellite/Regions-1/" xmlns:sat="http://www.elsevier.com/xml/schema/rdf/LDR-Satellites/Base-1/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:tag="http://www.elsevier.com/xml/schema/rdf/LDR-Satellites/TagAnnot-1/" xmlns:ecm="http://www.elsevier.com/xml/schema/rdf/common/Metadata-1/" xmlns:pmi="http://prismstandard.org/namespaces/pmi/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <sat:Satellite rdf:about="http://data.elsevier.com/metadata/BAM-1/pii:S2405844017316936">
      <sat:describesResource rdf:resource="http://vtw.elsevier.com/content/pii/S2405844017316936"/>
      <sat:describesResource rdf:resource="http://api.elsevier.com/content/article/DOI:10.1016/j.heliyon.2017.e00438"/>
      <sat:describesResource rdf:resource="http://api.elsevier.com/content/article/PII:S2405-8440(17)31693-6"/>
      <sat:satellite-type rdf:resource="http://data.elsevier.com/namespaces/LDR-Satellites/BasicAssetMetadata-1/"/>
      <sat:project rdf:resource="http://data.elsevier.com/enh-project/VTW"/>
      <pav:createdBy rdf:resource="http://data.elsevier.com/enh-service/LDR-VTW-INT"/>
      <pav:createdOn>2019-10-29T13:19:18Z</pav:createdOn>
    </sat:Satellite>
    <rdf:Description rdf:about="http://data.elsevier.com/metadata/BAM-1/pii:S2405844017316936">
      <dct:title>Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors</dct:title>
      <dct:isPartOf rdf:resource="http://vtw.elsevier.com/content/pii/S2405844016X00230"/>
      <bam:orderedCreatorList>
        <rdf:Seq>
          <rdf:li>Dipnarine Maharaj</rdf:li>
          <rdf:li>Pedro G. Vianna</rdf:li>
          <rdf:li>Wendy Ward</rdf:li>
          <rdf:li>Anthony J. Messina</rdf:li>
          <rdf:li>Trevor Rayborn</rdf:li>
          <rdf:li>Jacqueline V. Gouvea</rdf:li>
          <rdf:li>Richard D. Hammer</rdf:li>
          <rdf:li>Zheng Cui</rdf:li>
        </rdf:Seq>
      </bam:orderedCreatorList>
      <dct:creator>Dipnarine Maharaj</dct:creator>
      <dct:creator>Pedro G. Vianna</dct:creator>
      <dct:creator>Wendy Ward</dct:creator>
      <dct:creator>Anthony J. Messina</dct:creator>
      <dct:creator>Trevor Rayborn</dct:creator>
      <dct:creator>Jacqueline V. Gouvea</dct:creator>
      <dct:creator>Richard D. Hammer</dct:creator>
      <dct:creator>Zheng Cui</dct:creator>
      <dct:date>2017-10-31</dct:date>
      <dct:modified>2017-10-24T00:00:00Z</dct:modified>
      <dct:created>2017-06-27T00:00:00Z</dct:created>
      <dct:publisher>Elsevier Ltd</dct:publisher>
      <dct:language>en</dct:language>
      <dct:type rdf:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1.1"/>
      <dct:abstract>Abstract Background In the past decade, a variety of immunotherapy approaches focused predominantly on the adaptive immune system have shown unprecedented responses in patients with advanced-stage malignancies. However, studies in spontaneous regression/complete resistance (SR/CR) mice and humans have shown a novel innate cancer-killing activity mediated by granulocytes, which is completely transferable for prevention or therapy against established malignancies. Methods Three patients with advanced, relapsed or refractory solid tumors for which no standard therapy was available or was refused were enrolled into this ongoing combined phase I/II open label clinical trial testing the safety, dose tolerance, and possible antineoplastic efficacy of sequential infusions of HLA-mismatched non-irradiated allogeneic white cells (68–91% granulocytes) collected by leukapheresis from young, healthy donors (age 18–35) following mobilization with granulocyte colony stimulating factor (G-CSF) and dexamethasone. Results Besides fevers and flushing, no infusional toxicities were observed. All patients remained clinically stable following infusions with mild cytokine release syndrome and no evidence of transfusion-associated graft-versus-host disease, acute tumor lysis syndrome,or transfusion-associated acute lung injury. Pathological examination of all cases post-mortem revealed extensive tumor necrosis up to 80% in patients 1–2, 40–50% in patient 3, and leukocyte infiltration in all cases, which could not be attributed to disease progression. Conclusions Allogeneic white cell immunotherapy (AWIT) from young, healthy donors is well tolerated with minimal side effects and shows antitumor activity against advanced-stage solid tumors. AWIT represents a novel, safe, and cost-effective immunotherapy that can be administered in an outpatient cancer clinic.</dct:abstract>
      <bam:year>2017</bam:year>
      <bam:subtype rdf:resource="http://data.elsevier.com/vocabulary/ElsevierPubItemTypes/FLA"/>
      <prism:copyright>The Authors</prism:copyright>
      <prism:publicationName>Heliyon</prism:publicationName>
      <prism:issn>2405-8440</prism:issn>
      <prism:aggregationType rdf:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1"/>
      <prism:coverDisplayDate>October 2017</prism:coverDisplayDate>
      <prism:volume>3</prism:volume>
      <prism:number>10</prism:number>
      <prism:keyword>Health sciences</prism:keyword>
      <prism:keyword>Medicine</prism:keyword>
      <prism:keyword>Internal medicine</prism:keyword>
      <prism:keyword>Evidence-based medicine</prism:keyword>
      <prism:keyword>Oncology</prism:keyword>
      <prism:keyword>pharmaceutical science</prism:keyword>
      <prism:keyword>Systems biology</prism:keyword>
      <prism:keyword>Cancer research</prism:keyword>
      <dct:description>In the past decade, a variety of immunotherapy approaches focused predominantly on the adaptive immune system have shown unprecedented responses in patients with advanced-stage malignancies. However, …</dct:description>
      <prism:channel rdf:resource="http://data.elsevier.com/vocabulary/ElsevierContentTypes/1.1.1"/>
      <ecm:identifier>pii:S2405844017316936</ecm:identifier>
      <dct:identifier>HELIYON_2017_1625</dct:identifier>
      <bam:formattedPII>S2405-8440(17)31693-6</bam:formattedPII>
      <prism:doi>10.1016/j.heliyon.2017.e00438</prism:doi>
      <bam:publicationTimeStart>2017-10-01T00:00:00Z</bam:publicationTimeStart>
      <bam:publicationTimeEnd>2017-10-31T23:59:59Z</bam:publicationTimeEnd>
    </rdf:Description>
  </rdf:RDF>